Dedicated to the pursuit of justice

Bisphosphonates / Fosamaz

FDA safety investigations into the class of drugs containing bisphosphonates began in 2007, in response to an article published in The New England Journal of Medicine, which claimed that the drug caused increased rates of atrial fibrillation. Since that time, bisphosphonates have been investigated for their relationship to numerous alarming medical conditions, including but not limited to: atypical femur fractures and osteonecrosis of the jaw. CaseyGerry is currently accepting cases involving the following bisphosphonates: Aredia, Fosamax and Zometa.


While the U.S. Food and Drug Administration (FDA) continues to evaluate the safety risks associated with the use of Bisphosphonates for the treatment and prevention of osteoporosis, CaseyGerry is accepting cases against Merck & Co, the manufacturer of the popular drug, Fosamax.

Fosamax has been shown to cause atypical femur fractures in women who have been prescribed the drug as an attempt to combat, or prevent osteoporosis.

You may have been prescribed Fosamax if:

  • You have been diagnosed with Osteoporosis (severe low bone density)
  • You have been diagnosed with Osteopenia (mild low bone density)
  • You are post-menopausal
  • You have had a hysterectomy

The FDA warns that if you are currently taking Fosamax, to ask your doctor to reconsider whether Fosamax is the most appropriate medication for you. Most importantly, if you are experiencing a dull or aching pain in your thigh, just below the hip, contact your physician immediately.

If you believe that you or a loved one may have been injured as the result of a Fosamax, the attorneys at CaseyGerry can help. Contact us for a free consultation and case review.

Free Consultation

  • Required
  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.